Frontier Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Frontier Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-610	Closed	-$300K	–	239
2017 Q2	$300K	Hold	610	–	–	0.03%	180
2017 Q1	$236K	Buy	610 +60	+11%	+$22.2K	0.02%	175
2016 Q4	$202K	Hold	550	–	–	0.02%	181
2016 Q3	$221K	Buy	+550	New	+$221K	0.02%	178
2016 Q1	–	Sell	-561	Closed	-$299K	–	182
2015 Q4	$299K	Buy	561 +11	+2%	+$5.96K	0.05%	127
2015 Q3	$256K	Buy	+550	New	+$295K	0.04%	144

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Frontier Investment Management's REGN Position: Q3 2017 in Review

Frontier Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2017, closing a stake of 610 shares — an estimated $300K sold.

Frontier Investment Management first reported a position in REGN in Q3 2015 and held it in 6 quarters. The position peaked at $300K in Q2 2017. 606 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

Frontier Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Frontier Investment Management sold 610 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $300K.
Frontier Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 6 quarters.
Frontier Investment Management's Regeneron Pharmaceuticals position peaked at $300K in Q2 2017.
606 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on Frontier Investment Management's 13F filing for Q3 2017, filed 9 Nov 2017.